David Altshuler's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 52 Common Stock done at an average price of $424.7 . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 424.69 per share. | 15 May 2025 | 52 | 23,281 (0%) | 0% | 424.7 | 22,084 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 510.00 per share. | 13 Mar 2025 | 3,231 | 23,281 (0%) | 0% | 510 | 1,647,810 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 500.00 per share. | 10 Mar 2025 | 3,231 | 26,512 (0%) | 0% | 500 | 1,615,500 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 490.00 per share. | 03 Mar 2025 | 3,231 | 29,743 (0%) | 0% | 490 | 1,583,190 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 5,954 | 34,246 (0%) | 0% | 479.6 | 2,855,598 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.00 per share. | 26 Feb 2025 | 1,272 | 32,974 (0%) | 0% | 480 | 610,560 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,971 | 41,048 (0%) | 0% | 483.3 | 1,919,105 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.95 per share. | 24 Feb 2025 | 848 | 40,200 (0%) | 0% | 481.0 | 407,846 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 480.00 per share. | 20 Feb 2025 | 1,111 | 45,019 (0%) | 0% | 480 | 533,280 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,293 | 46,130 (0%) | 0% | 463.5 | 1,062,714 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,324 | 48,423 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,142 | 43,099 (0%) | 0% | 468.0 | 1,002,413 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 12,314 | 38,127 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 45,241 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 478.53 per share. | 15 Nov 2024 | 15 | 25,813 (0%) | 0% | 478.5 | 7,178 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 430.93 per share. | 15 May 2024 | 54 | 25,813 (0%) | 0% | 430.9 | 23,270 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 4,239 | 25,813 (0%) | 0% | 425.7 | 1,804,542 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,970 | 30,052 (0%) | 0% | 431.8 | 1,714,206 | Common Stock |
| Vertex Pharma | Altshuler David | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 3,002 | 34,022 (0%) | 0% | 421.8 | 1,266,154 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 4,002 | 37,024 (0%) | 0% | 420.8 | 1,684,002 | Common Stock |
| Vertex Pharma | Altshuler David | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 43,838 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 41,026 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 3,145 | 47,588 (0%) | 0% | 420.2 | 1,321,655 | Common Stock |
| Vertex Pharma | Altshuler David | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,099 | 50,733 (0%) | 0% | 422.7 | 887,331 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 45,718 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Altshuler David | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 52,832 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Altshuler David | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 37,852 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 345.51 per share. | 09 Aug 2023 | 63 | 32,038 (0%) | 0% | 345.5 | 21,767 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,970 | 36,276 (0%) | 0% | 289.1 | 1,147,806 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 287.23 per share. | 24 Feb 2023 | 3,636 | 32,640 (0%) | 0% | 287.2 | 1,044,368 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 289.60 per share. | 24 Feb 2023 | 302 | 32,038 (0%) | 0% | 289.6 | 87,459 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 288.74 per share. | 24 Feb 2023 | 300 | 32,340 (0%) | 0% | 288.7 | 86,622 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 44,248 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 294.03 per share. | 17 Feb 2023 | 1,843 | 41,146 (0%) | 0% | 294.0 | 541,897 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 292.76 per share. | 17 Feb 2023 | 1,223 | 42,989 (0%) | 0% | 292.8 | 358,045 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 294.73 per share. | 17 Feb 2023 | 900 | 40,246 (0%) | 0% | 294.7 | 265,257 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 291.00 per share. | 17 Feb 2023 | 36 | 44,212 (0%) | 0% | 291 | 10,476 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 299.08 per share. | 14 Feb 2023 | 2,165 | 50,194 (0%) | 0% | 299.1 | 647,508 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.11 per share. | 14 Feb 2023 | 1,888 | 48,306 (0%) | 0% | 300.1 | 566,608 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 296.85 per share. | 14 Feb 2023 | 842 | 52,754 (0%) | 0% | 296.9 | 249,948 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 295.79 per share. | 14 Feb 2023 | 800 | 53,596 (0%) | 0% | 295.8 | 236,632 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 297.97 per share. | 14 Feb 2023 | 395 | 52,359 (0%) | 0% | 298.0 | 117,698 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 301.02 per share. | 14 Feb 2023 | 308 | 47,998 (0%) | 0% | 301.0 | 92,714 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 59,194 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,461 | 65,184 (0%) | 0% | 294.3 | 1,018,676 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 298.47 per share. | 10 Feb 2023 | 2,160 | 56,789 (0%) | 0% | 298.5 | 644,695 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 299.36 per share. | 10 Feb 2023 | 1,893 | 54,896 (0%) | 0% | 299.4 | 566,688 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.23 per share. | 10 Feb 2023 | 500 | 54,396 (0%) | 0% | 300.2 | 150,115 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 296.44 per share. | 10 Feb 2023 | 245 | 58,949 (0%) | 0% | 296.4 | 72,628 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 06 Feb 2023 | 1,304 | 69,949 (0%) | 0% | 187.5 | 244,539 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 1,304 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 306.70 per share. | 06 Feb 2023 | 620 | 68,798 (0%) | 0% | 306.7 | 190,154 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 305.08 per share. | 06 Feb 2023 | 349 | 69,418 (0%) | 0% | 305.1 | 106,473 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 309.06 per share. | 06 Feb 2023 | 153 | 68,645 (0%) | 0% | 309.1 | 47,286 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 303.64 per share. | 06 Feb 2023 | 100 | 69,767 (0%) | 0% | 303.6 | 30,364 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 302.00 per share. | 06 Feb 2023 | 70 | 69,867 (0%) | 0% | 302 | 21,140 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.42 per share. | 06 Feb 2023 | 12 | 69,937 (0%) | 0% | 300.4 | 3,605 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 48,465 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,314 | 60,779 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 68,645 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 308.62 per share. | 15 Nov 2022 | 34 | 36,077 (0%) | 0% | 308.6 | 10,493 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 07 Nov 2022 | 1,303 | 37,380 (0%) | 0% | 187.5 | 244,352 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 1,303 | 1,304 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 304.58 per share. | 07 Nov 2022 | 280 | 36,300 (0%) | 0% | 304.6 | 85,282 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 303.21 per share. | 07 Nov 2022 | 261 | 36,580 (0%) | 0% | 303.2 | 79,138 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 300.96 per share. | 07 Nov 2022 | 210 | 37,030 (0%) | 0% | 301.0 | 63,202 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 301.99 per share. | 07 Nov 2022 | 189 | 36,841 (0%) | 0% | 302.0 | 57,076 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 305.39 per share. | 07 Nov 2022 | 140 | 36,160 (0%) | 0% | 305.4 | 42,755 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 299.72 per share. | 07 Nov 2022 | 140 | 37,240 (0%) | 0% | 299.7 | 41,961 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 306.57 per share. | 07 Nov 2022 | 83 | 36,077 (0%) | 0% | 306.6 | 25,445 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 1,304 | 2,607 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 08 Aug 2022 | 1,304 | 37,381 (0%) | 0% | 187.5 | 244,539 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 291.53 per share. | 08 Aug 2022 | 424 | 36,735 (0%) | 0% | 291.5 | 123,609 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 293.99 per share. | 08 Aug 2022 | 302 | 36,223 (0%) | 0% | 294.0 | 88,785 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 290.32 per share. | 08 Aug 2022 | 222 | 37,159 (0%) | 0% | 290.3 | 64,451 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 293.02 per share. | 08 Aug 2022 | 210 | 36,525 (0%) | 0% | 293.0 | 61,534 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 295.14 per share. | 08 Aug 2022 | 146 | 36,077 (0%) | 0% | 295.1 | 43,090 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2022 | 10,427 | 3,911 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 19 Jul 2022 | 10,427 | 46,604 (0%) | 0% | 187.5 | 1,955,375 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2022 | 7,338 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 19 Jul 2022 | 7,338 | 53,942 (0%) | 0% | 155.6 | 1,141,573 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 289.48 per share. | 19 Jul 2022 | 6,604 | 36,077 (0%) | 0% | 289.5 | 1,911,726 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 288.67 per share. | 19 Jul 2022 | 5,737 | 42,681 (0%) | 0% | 288.7 | 1,656,100 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 287.83 per share. | 19 Jul 2022 | 4,561 | 48,418 (0%) | 0% | 287.8 | 1,312,793 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 286.72 per share. | 19 Jul 2022 | 963 | 52,979 (0%) | 0% | 286.7 | 276,111 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 6,038 | 43,649 (0%) | 0% | 227.9 | 1,375,819 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 230.62 per share. | 24 Feb 2022 | 3,188 | 39,421 (0%) | 0% | 230.6 | 735,217 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 231.64 per share. | 24 Feb 2022 | 2,784 | 36,637 (0%) | 0% | 231.6 | 644,886 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 229.41 per share. | 24 Feb 2022 | 1,040 | 42,609 (0%) | 0% | 229.4 | 238,586 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 232.68 per share. | 24 Feb 2022 | 560 | 36,077 (0%) | 0% | 232.7 | 130,301 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 3,439 | 53,999 (0%) | 0% | 232.5 | 799,602 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 230.05 per share. | 17 Feb 2022 | 1,303 | 51,710 (0%) | 0% | 230.0 | 299,755 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 233.27 per share. | 17 Feb 2022 | 1,038 | 49,687 (0%) | 0% | 233.3 | 242,134 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 229.22 per share. | 17 Feb 2022 | 986 | 53,013 (0%) | 0% | 229.2 | 226,011 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 231.85 per share. | 17 Feb 2022 | 600 | 50,725 (0%) | 0% | 231.9 | 139,110 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 231.01 per share. | 17 Feb 2022 | 385 | 51,325 (0%) | 0% | 231.0 | 88,939 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 232.02 per share. | 14 Feb 2022 | 2,444 | 57,438 (0%) | 0% | 232.0 | 567,057 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 3,518 | 62,179 (0%) | 0% | 237.7 | 836,369 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 233.92 per share. | 10 Feb 2022 | 841 | 61,338 (0%) | 0% | 233.9 | 196,727 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 234.95 per share. | 10 Feb 2022 | 757 | 60,581 (0%) | 0% | 234.9 | 177,857 | Common Stock |
| Vertex Pharma | David Altshuler | EVP, Global Research and CSO | Sale of securities on an exchange or to another person at price $ 236.28 per share. | 10 Feb 2022 | 601 | 59,980 (0%) | 0% | 236.3 | 142,004 | Common Stock |